drugset / Trial / NCT01480310
Study to Investigate the Safety, Pharmacokinetics, and Immunogenicity of Subcutaneous MCAF5352A in Healthy Volunteers
RandomizedSingle-groupDouble-blindTreatment
Summary
This is a Phase Ia, randomized, double-blind, placebo-controlled, single ascending dose (SAD) study in male and female healthy volunteers, aged 18-55 years, enrolled at a single study site in Canada.
Timeline
- Start
- 2011-12
- Primary completion
- 2012-06
- Completion
- 2012-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AFASEVIKUMAB | Monoclonal antibody | — | Subcutaneous |
Indications
No indication recorded.